EPO Dosing Questions Left Unanswered; More Data, More Meetings Needed
Executive Summary
Amgen does not currently have enough data to characterize the relationship between targeted hemoglobin levels in patients receiving erythropoiesis-stimulating agents and clinical outcomes in the oncologic setting
You may also be interested in...
Medicare ESA Policy May Find Support In FDA Letter But J&J Sees Differently
Key Democratic legislators are spotlighting an FDA letter on erythropoiesis-stimulating agents as indicating agreement between FDA and Medicare policies, but some stakeholders interpret it as pointing out differences between the agencies
Medicare ESA Policy May Find Support In FDA Letter But J&J Sees Differently
Key Democratic legislators are spotlighting an FDA letter on erythropoiesis-stimulating agents as indicating agreement between FDA and Medicare policies, but some stakeholders interpret it as pointing out differences between the agencies
EPO Quality Of Life Claims Unsubstantiated, FDA Says, May Be Cut From Label
FDA is considering deleting patient-reported outcomes claims from epoetin alfa labeling, the agency announced during an advisory committee review of the anemia drug